Li Ke, Wang Feng, Hu Zhuo-Wei
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Mol Cell Oncol. 2017 Jun 16;4(4):e1337547. doi: 10.1080/23723556.2017.1337547. eCollection 2017.
Pseudokinase tribbles (Trib) family, and , but not , act as oncogene to drive acute leukemia by destabilizing the myeloid transcription factor CCAAT/enhancer-binding protein α (C/EBPα) and inhibiting myeloid differentiation. A recent study identifies pseudokinase TRIB3 as an important factor in acute promyelocytic leukemia (APL) progression and therapy resistance. Targeting TRIB3 may provide a novel therapeutic approach for APL.
假激酶TRIBbles（Trib）家族中的TRIB1和TRIB2而非TRIB3，作为癌基因通过使髓系转录因子CCAAT/增强子结合蛋白α（C/EBPα）不稳定并抑制髓系分化来驱动急性白血病。最近一项研究确定假激酶TRIB3是急性早幼粒细胞白血病（APL）进展和治疗耐药的一个重要因素。靶向TRIB3可能为APL提供一种新的治疗方法。
